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The ERK signaling cascade is a central MAPK pathway that plays a role in the regulation of various cellular processes such as proliferation,
differentiation, development, learning, survival and, under some conditions, also apoptosis. The ability of this cascade to regulate so many distinct,
and even opposing, cellular processes, raises the question of signaling specificity determination by this cascade. Here we describe mechanisms that
cooperate to direct MEK-ERK signals to their appropriate downstream destinations. These include duration and strength of the signals, interaction
with specific scaffolds, changes in subcellular localization, crosstalk with other signaling pathways, and presence of multiple components with
distinct functions in each tier of the cascade. Since many of the mechanisms do not function properly in cancer cells, understanding them may shed
light not only on the regulation of normal cell proliferation, but also on mechanisms of oncogenic transformation.
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Even though cells are surrounded by a membrane that
provides a separation between the outer and inner environ-
ments, they are able to respond to extracellular stimuli such as
mitogens and hormones, and convert their signals into cellular
processes. This conversion is usually mediated by the binding
of extracellular ligands to specific transmembranal receptors,
which are consequently activated to further transmit the signals
of the different ligands through intracellular signaling pathways.
These pathways, operating within complex networks of
interacting proteins, transmit the signals to various intracellular
targets, thereby regulating inducible cellular processes such as
transcription, translation, proliferation, differentiation and
apoptosis. Central building blocks in the intracellular signaling
network are the mitogen-activated protein kinase (MAPK)
cascades [1–4]. Transmission of signals via these cascades is
usually initiated by activation of a small G protein (e.g., Ras),
which is followed by a sequential activation of several sets of
cytoplasmic protein kinases. Each of the cascades is composed
of three to five tiers (MAP4K, MAP3K, MAPKK, MAPK and⁎ Corresponding author. Tel.: +972 8 9343602; fax: +972 8 9344116.
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doi:10.1016/j.bbamcr.2006.10.005MAPKAPK), and three tiers out of them, MAP3K, MAPKK,
and MAPK are considered to be the core cascade. One or more
kinase component in each of these tiers phosphorylate and
activate components in the next tier, until a downstream
component phosphorylates target regulatory molecules that
initiate the required physiological process. Four distinct MAPK
cascades (ERK, JNK, p38 and BMK) have been elucidated,
although their number is likely to increase, due to the
identification of novel MAPKs that are not specified to any
known pathway [5]. Each of these cascades is named after the
subgroup of its MAPK component, but the MAPKK and, to
some extent, the other tiers, also contain components that are
selective to each cascade. All these cascades cooperate in
transmitting signals from many ligands, and thereby determine
the cell's fate upon distinct extracellular stimulations. In this
review we focus on the extracellular signal-regulated kinase
(ERK) cascade, which was the first MAPK to be elucidated [6],
and describe mainly the components in the MAPKK and
MAPK tiers of the cascade (MEKs and ERKs). As other MAPK
cascades, the ERK cascade is activated by various stimuli, and
participates in the regulation of proliferation, differentiation,
survival, learning, apoptosis and more. We devote a big part of
the review to describe the mechanisms that dictate the signaling
specificity of the cascade, regulate its downstream activity, and
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processes.
2. Components and regulation of the ERK cascade
2.1. MAP3Ks and MEKs
The ERK cascade is activated by a large number of
extracellular stimuli and various internal processes. Upon its
activation, the cascade plays a central role in the induction of
processes such as proliferation, differentiation, development,
and under certain conditions also in cell survival, learning,
migration, apoptosis, morphology determination and oncogenic
transformation [6–9]. The signaling via this cascade (Fig. 1), is
usually initiated by activation of small G proteins (e.g. Ras),
which transmit the signal further by recruiting the MAP3K tier
Raf kinases to the plasma membrane, where they are activated
[10]. Other MAP3K components that participate in the
activation of ERKs under specific conditions are (i) c-Mos
that acts specifically in the reproductive system [11]; (ii) the
protooncogene TPL2 [12]; and (iii) MEKK1 [13] that acts
mainly under stress conditions. An additional protein kinase in
this tier might be the kinase suppressor of Ras (KSR), but the
role of its catalytic activity is still controversial [14], as it seems
to act mainly as a scaffold protein for the ERK cascade [15]. All
these MAP3Ks transmit the signals further by phosphorylating
and activating the MAPKK tier proteins, MAPK/ERK kinases
(MEKs; [16,17]), which funnel upstream signals into the
characteristic linear cascade, as observed in lower organisms
[18].
The MEKs constitute an evolutionarily conserved group of
three highly homologous (∼85%) mammalian isoforms
[19–21]. These isoforms are the 45 kDa MEK1, its alternativelyFig. 1. Schematic representation of the ERK signaling cascade. Activation and inactiv
arrows stand for the main pathway upon growth factor activation. For more details
Blue—inhibitory phosphorylation and dephosphorylation.spliced form, MEK1b (43 kDa) that is thought to be inactive,
and the 46 kDa MEK2. These proteins are composed of a
catalytic kinase domain, which is surrounded by a regulatory
N-terminal domain (∼80 amino acids) and a shorter C-terminal
region (∼30 amino acids). X-ray analysis of truncated human
MEK1 and MEK2 revealed that they are indeed similar in
structure to other protein kinases [22]. MEKs are activated by
phosphorylation of two Ser residues in their activation loop
(Ser218 and Ser222 in MEK1) located within a Ser–Xaa–Ala–
Xaa–Ser/Thr motif [23], typical to all MAPKKs. This
phosphorylation may be regulated in part by a direct interaction
of the domain for versatile docking (DVD) region in MEKs
with their upstream activators [24]. The activity of MEKs is
regulated by additional phosphorylation/dephosphorylation
processes as well. Amongst these are the phosphorylation of
Ser386 of MEK1 by ERKs [25], which can either inhibit ERKs
activity [26], or under other conditions, facilitate the activation
by enhancing the binding of MEK1 to the scaffold Grb10 [27].
Phosphorylation of Ser298 of MEK1 by p21-activating protein
(PAK1) plays an accessory role in MEKs' activation [28,29], a
process that can be inhibited by a feedback phosphorylation on
Thr292 of MEK1 by ERKs [30]. Several other phosphorylation
sites on MEK1, which might regulate its activity are detailed
elsewhere [31–33]. Finally, the downregulation of MEKs
involves a rapid dephosphorylation of pSer218 and pSer222,
mainly by the protein Ser/Thr phosphatase PP2A [34], but
possibly also other phosphatases.
Upon activation, MEKs act as dual specificity kinases and
phosphorylate the regulatory Tyr and Thr residues of ERKs at
the next tier of the cascade, thereby causing their activation
[35]. Importantly, ERKs seem to be the only physiological
substrates of MEKs, suggesting that these kinases serve as the
specificity determining components of the ERKs within theation processes are indicated. Dashed lines indicate indirect activations, and bold
see text. Red—activatory phosphorylation. Green—accessory phosphorylation.
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to function as cytoplasmic anchor proteins for ERKs [36,37]. In
addition, it was shown that MEKs translocate into the nucleus of
resting cells [38], and this process is facilitated upon stimulation
[39,40]. However, the nuclear MEKs are rapidly exported out of
this location by a NES region in their N-terminal domain. This
shuttling allows MEKs to serve as a nuclear exporting platform
that operates on ERKs [41], PPARγ, and possibly other nuclear
proteins. In addition, this translocation is probably required for
the phosphorylation of the nuclear ERK isoforms such as
ERK1b and ERK1c [42,43].
2.2. ERKs and MAPKAPKs
The next tier in the cascade, which contains the MAPK
components, is composed of the ERK proteins that are the
evolutionary conserved products of the two genes, erk1
(Mapk3) and erk2 (Mapk1) [44–46]. Aside from the two
main protein products, the 44 kDa ERK1 and the 42 kDa ERK2,
several other alternatively spliced forms have been described,
including the rodent 46 kDa ERK1b [42], the primate ERK1c
[43] and the ERK2b [47]. All these kinases are composed of a
catalytic kinase domain wrapped by regulatory stretches, and
also contain an unique insert sequence within their kinase
domain [46]. As mentioned above, the ERKs are all activated by
dual phosphorylation on their regulatory Tyr and Thr residues
located within the Thr–Xaa–Tyr motif [48]. This unique dual
phosphorylation seems to be mediated solely by MEKs, which
recognize only the native conformation of ERKs [35]. The
molecular mechanism that allows full activation of ERKs by
MEKs was extensively studied over the past decade. Mutational
analysis has uncovered a region located at the C-terminus of
ERKs (amino acids 312–320 in ERK2), important for its
interaction with MEKs [37,49]. This region was termed initially
cytoplasmic retention sequence (CRS), but was later shown
important for the interaction of ERKs with many other proteins,
and therefore, also termed common docking (CD) domain [50].
This region is one of the docking sites in the ERK molecule that
allows binding of the kinase to a variety of proteins as described
below. The most important interacting residues in this region are
three acidic amino acids (Asp316, Asp819 and Glu320 in
ERK2), as well as a few hydrophobic ones. This region was
shown to interact with three basic, and two hydrophobic
residues in the N terminus of MEKs, termed the D domain.
Other regions in ERKs that can contribute to the binding energy
between ERKs and MEKs are (i) the β7–β8 and αD-αE groove
that interacts mainly with the hydrophobic region of the D-
domain [51]; (ii) several residues within the kinase insert
domain in the C-terminal lobe that may either associate with
MEK or secure the proper conformation required for the
binding [52]; and (iii) possibly also the N terminal domain [53].
Crystallization studies have revealed that binding of the D
domain of MEKs to the CRS/CD domain of ERKs induces a
conformational change that exposes the regulatory Thr and Tyr
residues to the environment [54], and thereby allows the
attached MEKs to phosphorylate them. The phosphorylation
leaves out critical ion pair interactions between the phosphory-lated sites and the HRD motif and C-helix. This induces a
rotation and depression in the surface of the catalytic pocket of
ERKs to form a pocket that allows the binding of the ERKs'
substrates, and fits the phosphorylated Ser/Thr residue in the
substrate to its right position towards the γ phosphate of the
ATP [55,56]. These changes allow a full catalytic activity of the
ERK2, which is 5–6 orders of magnitude higher than its basal
activity [57].
The inactivation of ERKs is mainly mediated by removal of
the phosphates from either one, or both of the regulatory Thr or
Tyr residues of ERKs [58]. This process can be mediated by
either protein Ser/Thr phosphatases (PPs) such as PP2A [59], by
protein Tyr phosphatases, such as PTP-SL [60], or by dual
specificity phosphatases, generally termed MAPK phosphatases
(MKPs, [61]). Interestingly, the PTPs and MKPs interact with
the ERKs via a D domain, similar to that of MEKs [50]. Upon
binding, PTPs remove only the phosphate from the Tyr residues,
which is sufficient to induce complete inactivation of the ERKs
[35]. However, this initial dephosphorylation is usually
followed by removal of the second phosphate from the Thr
residue by the PPs, which is the reason for the lack of significant
amounts of pTyr-ERK in the cells [62]. MKPs inactivate
MAPKs by simultaneously removing phosphates from both
pTyr and pThr residues, although the dephosphorylation of pTyr
may slightly precede that of pThr [63]. Apart from the
downregulation by phosphatases, ERKs seem to participate in
multiple feedback loops that are important for the reduction of
their activity at later stages after stimulation (Fig. 1). These
include inhibitory phosphorylation of the upstream exchange
factor SOS [64], Rafs [65,66], and MEKs [29].
Upon phosphorylation of the regulatory Tyr and Thr
residues, ERKs become a potent protein Ser/Thr kinases,
which phosphorylate substrates on their consensus sites, which
is in most cases, Pro–Xaa–Ser/Thr–Pro [67]. However, the
shorter sequence Ser/Thr–Pro alone is sometime sufficient to
direct ERKs' phosphorylation, and the phosphorylation of SOS
seems to occur on a site that does not contain any adjacent Pro
residues [64]. In addition, many of the substrates can interact
with ERK via specialized docking domain including the D
domain described above for MEKs. Another important domain
on ERK interacting proteins is the docking site for ERK–FXF
(DEF domain), which consists of Phe–X–Phe–Pro consensus
sequence [68]. This site binds to a hydrophobic cluster in the
bigger lobe of ERKs known as the DEF binding domain [69].
Additional docking motifs in specific substrates are likely to
emerge in the future. Thus, the combination of docking motifs
together with catalytic site interactions, often function in a
tripartite manner to direct interactions between ERKs and their
substrates to participate in the determination of their substrate
specificity.
Upon stimulation, ERKs have been demonstrated to
phosphorylate a large number of substrates [9]. Some of these
substrates are localized in the cells' cytoplasm, while others are
phosphorylated in the nucleus by ERK molecules that are
translocated into this organelle upon stimulation [9]. Notably,
ERKs phosphorylate and activate a series of transcription
factors such as Elk1 [70], c-Fos [71], p53 [72], Ets1/2 [73], and
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regulation of proliferation and oncogenic transformation.
Alternatively, the ERKs can transmit the signal further by
phosphorylating and activating protein kinases at the MAP-
KAPK tier. The main MAPKAPK of the ERK cascade are the
90 kDa ribosomal S6 kinases RSKs [75], which can
independently translocate into the nucleus and phosphorylate
a distinct set of substrates there. Additional MAPKAPKs are the
mitogen- and stress-activated kinase (MSK; [76]), and the
MAPK-interacting kinases (MNKs; [77,78]), that are equally
activated by the related p38 cascade or by other kinases [79].
Finally, MAPKAPK3 [80], and MK5 [81] are only slightly
activated by ERKs, as they are more responsive to p38s [82].
MAPKAPKs can regulate the activity of additional kinases (e.g.
Myt1 [83]), but these are usually not considered to be genuine
members of the ERK cascade. All the above substrates change
their activity upon ERKs phosphorylation, and thus regulate
ERKs-dependent processes upon most stimulations.
3. Specificity determination
The ability of ERKs to transmit different, and even opposing,
signals in the same cells raises the question as to how the
specificity of the different signals transmitted by the ERK
cascade is regulated. Several mechanisms that participate in this
specificity determination have been proposed in the past years
(Fig. 2), including: (i) duration and strength of the signals [84–
86]; (ii) interaction with various scaffold proteins [15,49,87];
(iii) subcellular localization [88,89]; (iv) extensive cross-talk
and interplay between the ERK cascade and other intracellular
signaling pathways [1]; and (v) presence of several similarFig. 2. Schematic representation of mechanisms that determine the sigisoforms, at each tier of the cascade [90], including alternatively
spliced forms [43], which are all described below. Although
these mechanisms could independently determine signaling
specificity, they are often cooperating with each other to secure
proper downstream effects. In addition, the effect of similar
ligands on different cells is influenced by other mechanisms,
such as the expression of specific substrates [9], but these
aspects are not discussed here.
3.1. Duration and strength of the signals
The first model that was proposed to explain signaling
specificity by the ERK cascade involved changes in the
duration and strength of the signals transmitted by the cascade
[84]. The model was mainly based on the kinetics of ERKs
activation in PC12 cells upon stimulation with EGF that
causes proliferation, as opposed to stimulation with NGF that
leads to neurite formation (differentiation). Thus, it was shown
that EGF stimulation causes a strong but transient activation of
the ERK cascade, while NGF causes an equally strong but
sustained activation [91]; both effects were shown to be
dependent on the activity of ERKs. It was also shown that
artificial prolongation of ERKs activity upon EGF stimulation
changes the effect of this factor to differentiation rather than
proliferation [92]. This correlation between the duration of
ERK activity and its effects on cellular processes has also been
observed in other systems such as oncogenic transformation of
fibroblasts [93], and even in yeast, where sustained activation
of the MAPK homolog KSS1 is required for filamentous
growth, while a transient activity of this kinase results in a
mating response [94]. It should be noted that much of thenaling specificity of the ERK cascade. For more details, see text.
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above), or through downregulation of upstream tiers of the
cascade [95].
The regulation of the kinetics of ERKs activation by
extracellular signal has been extensively studied in the past
decade, and was shown to involve several unrelated mechan-
isms that operate separately in each tier of the receptor-mediated
pathways [86,95]. However, less is known about the way by
which the duration of the signals influences the downstream
processes. Interestingly, such a mechanism has been recently
proposed by Murphy et al. [71,86,96], who demonstrated that
signal duration is likely to influence the transcription and
activity of immediate early genes, such as c-Fos, c-Jun, c-Myc
and Egr1. The most prominent example for this mechanism is
the transcription factor c-Fos, a known target of the ERK
cascade [86] that induces both its expression and stabilization
upon stimulation. Thus, when ERKs activation is transient, they
are able to induce the expression of c-Fos, although ERKs
activity declines before the c-Fos accumulates, which prevents
the stabilization of the latter. On the other hand, when ERKs
activity is sustained, c-Fos can be phosphorylated and activated
by ERKs and RSKs. As a consequence, the phosphorylated c-
Fos can induce expression of a larger repertoire of genes, and
thus participate in relatively late processes such as cell cycle
progression. Although this is an attractive mechanism, it cannot
explain all of the effects of a longer duration of ERKs activity.
Additional mechanisms, such as protection of ERK phosphor-
ylation by specialized interacting proteins [97], stabilization of
additional proteins [98], effects on chromatin remodeling [99],
and others, are likely to emerge as key steps in regulating ERKs
specificity and functions.
3.2. Scaffolds
A second mechanism that contributes to the specificity of the
ERK cascade is the formation of multi-protein complexes,
primarily due to interaction with scaffold proteins [49,87]. The
importance of scaffolds for MAPK signaling was first
demonstrated in yeast [100], where different scaffolds could
direct signaling components to regulate distinct processes. An
example is the Ste11 protein, which acts as a MAP3K of two
distinct pathways. In the mating response, Ste11p is recruited by
the scaffold protein Ste5p to interact with, and activate, the
MAPKK Ste7p and the MAPKs Fus3/Kss1 [101]. Conversely,
in response to osmotic pressure, Ste11p is recruited by the
MAPKK Pbs2, which serves as a scaffold that directs the
signals to the MAPK Hog1 [102]. Importantly, Ste5p not only
affects Ste11p signaling, but can also act as a switch between
the MAPKs, Fus3 and Kss1, in the mating response [103].
In the past few years, scaffold proteins were also implicated in
the regulation of signaling cascades in mammals [104]. For
example, the JNK cascade is highly regulated by several distinct
scaffold proteins, and other scaffolds have been identified for the
ERK and p38 signaling cascades [105]. Notably, most of these
scaffolds have a very little, or no sequence similarity to the yeast
scaffolds, and therefore, their effects need to be studiedmainly in
mammalian systems. The importance of scaffold proteins inmammals lies mainly in their ability to recruit proteins belonging
to a specific signal transduction event, and bring them to a close
proximity to each other [106]. In addition, scaffold proteins can
provide better stability to some of the cascade components, to
determine the threshold of signaling and lead to different
functions of a given cascade by recruiting of different substrates
to individual cascade components [87,107,108]. Finally,
scaffolds can determine the localization of the cascade
components [109], or protect signaling components from
phosphatases, thereby regulating their activity [97]. By doing
so, scaffold proteins induce faster kinetics of activation of their
signaling cascade, modify signaling duration and intensity,
secure better interaction between distinct signaling components,
regulate the localization of the cascade's proteins, and modify
crosstalk with other signaling pathways [87]. Thus, scaffolding
supports several other mechanisms that can independently
determine signaling specificity, and therefore, are key compo-
nents in the signaling of most cascades. It should be noted that
the term scaffold is usually reserved to proteins that interact
with at least two, or more often, three or four components of a
given cascade. Mono-interactions with certain component also
exist, but those are referred to as interacting or anchoring
proteins, rather than scaffolds. As of today, more than 50
scaffolding and anchoring proteins have been described for the
ERK cascade [49], and description of many of them is found in
another review in this issue. Nonetheless, several scaffolds that
play a key role in the determination of ERK cascade specificity
are described below.
One of the best studied scaffolds of the ERK cascade is the
KSR1, initially identified as a key component in the ERK
signaling in D. melanogaster and C. elegans [110–112].
Although KSR1 has high homology to Raf1, it is still
controversial whether it can physiologically phosphorylate
any substrate involved in ERK signaling [14]. In fact, many
studies support a kinase-independent function of KSR1 [113],
which appears to serve as a scaffold protein [15,114]. Thus, it
was demonstrated that in quiescent cells, KSR1 is associated
with MEKs [106], but not with ERKs or Raf kinases. In
addition, it interacts with c-Tak1, which constitutively phos-
phorylate its Ser392 [115], with the adaptor protein 14-3-3
[116], with inactive PP2A [117], and with the inhibitory E3
ubiquitin ligase, IMP1 [118], which assists in maintaining the
cytosolic localization of the KSR1 complex, [15]. Upon
stimulation, IMP1 is recruited by Ras-GTP, and this is followed
by a polyubiquitination of the IMP1 and its subsequent
degradation. In parallel, the associated PP2A is activated to
dephosphorylate Ser392 in KSR1, which is essential for
dissociation of 14-3-3 protein [115]. These two processes
together allow the rest of the KSR1 complex to translocate to
and interact with the plasma membrane, where it recruits an
activated Raf1 [118], which causes a facilitated activation of
MEKs. Simultaneously, ERKs are recruited to the activated
complex, and this facilitates their phosphorylation and activa-
tion [106], which are followed by the release of ERKs from the
complex. The released active ERKs are then able to translocate
to their sites of action in the cytoplasm or the nucleus and
induce most ERKs-dependent cellular functions [15].
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various stimulations, other scaffolds seem to attract portions of
the MEK and ERK molecules to specialized signaling events.
One such protein is β-arrestin [119], that participates in ERK
signaling upon G-protein-coupled-receptor (GPCRs) stimula-
tion [120]. The interaction of ERKs, as well as MEKs and Raf1
with β-arrestin seems to be irreversible [119], thereby, the β-
arrestin-facilitated activation of the ERK cascade in the
membrane prevents ERKs from translocating into the nucleus,
resulting in a preferential phosphorylation of cytoplasmic
substrates [121]. Another scaffold that directs the ERK cascade
to specific signaling is paxillin, which is a member of the focal
adhesion protein family that plays a central role in focal
adhesion assembly and is essential for cell spreading and
migration [122]. Interestingly, it was shown that upon
stimulation with hepatocyte growth factor, paxillin interacts
with components of the ERK cascade, to regulate epithelial
morphogenesis [123,124]. Similar to KSR1, paxillin seems to
be constitutively associated with MEKs, whereas ERKs and
Raf1 are recruited to paxillin only upon activation [123].
However, unlike KSR1, paxillin interaction partially prevents
the nuclear translocation of ERKs and directs ERKs' signal to
cytoplasmic targets. Other prominent scaffolds are Sef1 [125]
and MEK partner 1 (MP1 [126]), which seem to be responsible
mainly for directing the ERK cascade into certain compart-
ments within the cytoplasm, and therefore, will be described
under Subcellular localization below. Overall, it would appear
that many of the functions of the ERK cascade are funneled
through designated scaffolds, which dictate the kinetic,
localization, and components of the cascade, in determining
much of its specificity.
3.3. Subcellular localization
A third mechanism that contributes to the specificity of
the ERK cascade is the restriction of components of the
ERK cascade to specific cellular compartments, and the
dynamic changes in their localization after stimulation
[9,88,89]. These processes direct signaling components
such as Ras and constituents of the ERK cascade into
specific targets or organelles (e.g. Golgi [7,89]), where they
may induce distinct functions [127]. Therefore, the signaling
in one cellular compartment may have a different outcome
from a similar signaling event in another localization. For
examples, forcing nuclear localization of an ERK2–MEK1
chimera resulted in an increased transcriptional activity
[128], and forcing membranal association of ERKs resulted
in an attenuated transcriptional activity [129]. In addition it
was shown that restricted cytoplasmic ERK2 activity
protected, while ERK2 activation restricted to the nucleus
antagonized proapoptotic stimuli in myeloid leukemia cells
[130]. More on the molecular mechanisms that explain
these differences in signal propagation in distinct subcellular
localization are followed.
In resting cells, all components of the ERK cascade seem
to be localized primarily in the cytoplasm. The mechanisms
that govern this localization in resting cells are distinct for thedifferent components. The exact mechanisms that anchor Raf1
to the cytoplasm in close proximity to the plasma membrane
is not yet clear, but might involve interaction with liposomes,
lipid rafts, or other lipid moieties [131]. MEKs seem to be
localized in the cytoplasm of resting cells mainly due to its
nuclear export signal in its N-terminal domain [38,39]; it is
possible however, that residues in the C-terminal domain are
also involved in this localization [132]. Finally, the interaction
of MEKs with a large number of scaffold and anchoring
proteins [32] may contribute to their precise localization as
well.
ERKs and RSKs seem to be attracted to the cytoplasm,
mainly by a relatively strong interaction with a large number of
anchoring proteins. These anchors are probably responsible for
the diffuse cytoplasmic appearance of the kinases, as well as
their localization in specific microenvironments within the cells
[49]. Among these interacting proteins, one can find micro-
tubules [133] MEKs, [36,37], phosphatases [134], scaffolds,
and other anchoring proteins [49]. The interaction of ERKs with
many of these proteins is mediated by the cytoplasmic retention
sequence (CRS/CD) of ERKs [37,50]. Other anchoring
interactions might occur through different part of the ERK
molecule such as residues 91–95 of ERK2, responsible for the
interaction with microtubules [135], or even the DEF binding
domain in the bigger lobe of the kinase domain [69].
Interestingly, the interactions mediated by the CRS/CD seem
to be reversible due to conformational changes that occur upon
phosphorylation of ERKs [136], whereas interactions through
other regions in ERKs are more stable, as they are usually not
reversed upon cellular stimulation [133].
The cytoplasmic distribution of the components of the ERK
cascade is dramatically altered upon extracellular stimulation.
Thus, Raf1 is recruited to the plasma membrane due to its
interaction with activated Ras [137], while MEKs, ERKs and
RSKs are released from their cytoplasmic anchors, causing
much of their molecules to translocate into the nucleus [39,138].
Since these components of the ERK cascade do not contain
nuclear localization signal (NLS), the mechanism of their
nuclear translocation is not fully understood. It was shown that
the ERKs [41] as well as MEKs [139] translocate to the nucleus
using either a non-regulated or a facilitated mechanisms. The
facilitated mechanism was proposed to require homodimeriza-
tion of ERKs that may occur upon extracellular stimulation
[41,140]. However, other studies found that mutating the
dimerization sites does not significantly influence the stimu-
lated translocation [136], and therefore, the importance of
dimerization is still controversial. Recently, it was shown that
this cyto-nuclear shift may occur by a direct interaction with
several nuclear pore proteins (NUPs, [141,142]) but more
studies are required in order to fully elucidate the mechanisms
of nuclear translocation of ERKs and MEKs. Shortly after
stimulation, MEKs are exported from the nucleus by the
exportin system that utilizes their NES sequence [39]. ERKs
and RSKs stay in that location longer, possibly due to the
interaction with newly synthesized nuclear anchors [143].
Interestingly, the ability of MEKs to undergo nucleocytoplas-
mic shuttling may also result in a MEKs-induced export of
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initial basal conditions.
As mentioned above, the localization of ERKs, both before
and after stimulation, is largely dependent on their interaction
with various regulatory proteins. One such protein is phospho-
protein enriched in astrocytes (PEA-15), a widely expressed 15-
kDa protein with a death-effector-domain [145,146]. In the
cytoplasm, PEA-15 binds ERKs, but not any other component of
the ERK cascade. This binding prevents ERKs' nuclear
translocation, without inhibiting their kinase activity, therefore,
causing a reduction in the nuclear activity of ERKs without
much effect on the cytoplasmic activity [145]. The mechanism
by which PEA-15 prevents nuclear translocation of ERKs is still
unclear, but may involve PEA-15-dependent interference with
ERKs' binding to NUPs [146]. Alternatively, it is possible that
the NES of PEA-15 attracts ERKs to the cytoplasm, as
previously reported for MEKs. Thus, PEA-15 acts as a
cytoplasmic regulator that redirects ERKs' signaling to different
targets.
Another protein that influences ERKs and MEKs localiza-
tion is the MP1 [126]. This is a 13.5 kDa protein, which
interacts with MEK1 and ERK1, but not with MEK2 and
ERK2. In vivo studies demonstrated that MP1 does not
significantly enhance ERK1 activation, indicating that MP1
may play another role in the regulation of the ERK cascade.
Indeed, it was later found that the MP1–ERK1 complex can
interact with the endosomal protein P14, which directs the
localization of ERK1 and MEK1 to the endosomes/lysosomes,
where they execute a distinct regulatory function [147].
Interestingly, MP1 can also interact with the scaffold protein
MORG1, which directs it to different compartments, allowing it
to regulate another set of intracellular signals [148]. Finally
ERKs and MEKs can interact with an additional anchoring
protein, termed Sef1, which direct MEKs and ERKs to the
Golgi apparatus, prevents nuclear translocation of ERKs and
may regulate cell cycle [7,125]. In summary, the localization of
components of the ERK cascade, determined by specific
sequences in ERKs MEKs and their interacting proteins, is
important in directing signals to their appropriate substrates, and
thereby, is a key component in dictating signaling specificity of
the ERK cascade.
3.4. Cross-talk and interplay with other cascades
A fourth mechanism that contributes to the specificity of the
ERK cascade is the interplay of the cascade with other signaling
cascades. Although the 3–5 tiers of the ERK cascade usually
form a linear pathway, several other signaling cascades can
regulate the activity of components in several tiers of the
cascade, and thus, modify their activation upon distinct
physiological conditions. These modifications, which usually
affect the kinetics strength and localization of the signals, are
mediated mostly due to phosphorylation/dephosphorylation by
kinases and phosphatases that are not always part of the ERK
cascade. In addition, many of the signals by other cascades are
likely to converge with that of the ERK cascade at downstream
components, such as transcription factors and downregulatingmolecules [1], but this will not be discussed much in the current
review. On the other hand, we bring here two examples of direct
effects by unrelated cascades that can either activate or inhibit
the ERKs signaling, and thereby significantly influence the
specificity of the signals.
One of the signaling pathways that contributes to the
activation of the ERK cascade is the Rac1/CDC42-PAK1
cascade. Rac1 and cdc42 are members of the Rho subfamily of
small GTP binding proteins, which are activated by cell
adhesion, to mediate lamellipodia extension and focal adhesion
formation through the downstream effector, PAK1 [149]. The
localization and activation of PAK1 in focal adhesion
complexes lead to dynamic changes in cytoskeleton organiza-
tion, which is often mediated by phosphorylation and activation
of LIM kinase [150], or by inhibition of myosin light chain
kinase [151]. Interestingly, aside from these kinases, PAK1 can
also phosphorylate MEK1 in the focal adhesion complexes,
which is an important step in the regulation of cell adhesion and
spreading. Therefore, this phosphorylation is a site of
convergence for integrin and growth factor signaling [28, 29].
In the past few years, the role of MEKs phosphorylation by
PAK1 has been elucidated. Thus, adhesion of fibroblasts to
fibronectin induces PAK1-dependent phosphorylation of
MEK1 on Ser298. This phosphorylation is insufficient to
induce activation of MEK1, a process that is mediated under
these conditions by Raf1-induced phosphorylation of residues
Ser218 and Ser222. However, this phosphorylation seems to
support association of MEK1 with Raf1 [28], and to further
enhance the association of MEK1 with ERKs that generates a
more efficient activation of the ERK cascade in newly adhering
cells [152]. Interestingly, the phosphorylation of MEK1 by
PAK1 is subjected to a negative feedback regulation, as it was
demonstrated that upon activation, ERKs can phosphorylate
Thr292 of MEK1 [153], which is located in close proximity to
the PAK1 phosphorylation site. This additional phosphorylation
was recently shown to block the ability of PAK1 to
phosphorylate Ser298, and thereby, reduce the Rac1-PAK1-
dependent MEK1-ERKs complex formation [30]. Therefore,
this phosphorylation is likely to participate in the down-
regulation of the ERK cascade in later stages after stimulation,
which seems to be a common negative feedback loop of the
ERK cascade, also operating on Sos and Raf kinases (Fig. 1). It
was recently reported that inhibition of PAK1 did not affect
MEK1 activity induced by EGF, although it did affect the
activity induced by PDGF [154]. Moreover, the scaffold
complex MP1-p14 seems to participate in this differential
regulation as it allows MEK1, not MEK2 activation upon
adhesion, but not PDGF stimulations [155]. Therefore, the
phosphorylation by PAK1 provides a mechanism to confer
specificity upon certain converging stimulations.
Another group of kinases that may participate in the
regulation of the ERK cascade, and therefore, exhibit a crosstalk
between two regulatory systems is the cyclin dependent kinases
(CDKs). This group is composed of several Ser/Thr kinases that
are key components in the regulation of cell cycle progression
[156]. Several studies demonstrated that members of this family,
such as CDK1 [153] and CDK5 [157], can phosphorylate
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these kinases is likely to play a role in different stages of the cell
cycle, as CDK1 is a key regulator of the G2/M phase of the cell
cycle [156], while CDK5 may participate in cell cycle-
independent processes [158]. Both CDKs were demonstrated
to phosphorylate MEK1 on Thr286 and Thr292 [153,157,159].
However, unlike the PAK1-dependent phosphorylation, which
acts as a positive regulator, the CDKs phosphorylation leads to
the inhibition of MEK1 activity. This is probably not due to
reduction of PAK1 activity, as proposed for ERKs phosphor-
ylation on Thr292 described above, since the inhibition was
observed under conditions with no PAK1 activation. A
mechanism that was proposed for this inhibition was a
phosphorylation-dependent photolytic cleavage of MEK1 at
its N-terminal ERK-binding domain [159]. It should be noted
however, that the role of CDKs in MEK1 regulation is still
controversial, as a recent study demonstrated that the phosphor-
ylation of Thr286 of MEK1 is unable to inhibit constitutively
active MEK1 [160], and it is, thus far, not clear how Thr292
phosphorylation induces cleavage of the N-terminus of MEK1.
Nonetheless, it is clear that CDKs can regulate ERKs activation
during cell cycle progression [160], and this, as well as the
phosphorylation by PAK1, provides a tool to determine the
specificity of the ERK cascade under unique conditions.
3.5. Multiple isoforms in each tier of the cascade
A fifth specificity-determining mechanism might be the
existence of various components with distinct regulations or
functions in each tier of the ERK cascade. Indeed, the MAP3K
tier of the cascade contains quite a few components, including
Raf kinases, c-Mos, TPL2, MEKK1 and others, which operate
under distinct conditions as described in other reviews in this
issue [4]. On the other hand, the extensive sequence similarity
between the components in the next tiers (MEKs and ERKs),
and their identical substrate recognition, led to the initial
conclusion that the isoforms in these tiers (MEK1 and MEK2 as
well as ERK1 and ERK2) are functionally redundant. However,
based on some biochemical, and especially genetic studies, it is
now clear that some differences in regulation between the
different isoforms do exist. In addition, the existence of specific
alternative spliced isoforms of the ERKs and MEKs clearly
extend the number of targets, and thereby, expand the number of
processes regulated by the ERK cascade. Some of these
components and their specific targets are described below.
In the MEK tier, MEK1 and MEK2 are ∼80% identical to
each other [21], and are essentially identical in most of their
kinase domain. In accordance to this similarity, it was initially
shown that MEK1 and MEK2 phosphorylate ERKs equally
well, both in vivo and in vitro. Moreover, the constitutively
active MEK1 and MEK2 mediate the activation of similar
transcriptional and morphological responses [161], and both
MEKs are required for proliferation in HeLa cells [162].
However, unlike the kinase domains, the N-termini and the
characteristic Pro-rich inserts (residues 285–296 that are
phosphorylated by PAK1, ERKs and CDKs, as described
above), are quite divergent between the two MEKs (40%identity). Indeed, differential functions of MEK1 and MEK2
were demonstrated using MEK1 and MEK2 knockout mice.
Thus, knockout of MEK1 causes an embryonic lethality of the
MEK1−/− mice, which die at 10.5 days of gestation, due to a
lack of angiogenesis in the labyrinthine region of the placenta.
[163]. On the other hand, MEK2−/− mice are viable and fertile,
with no observed morphological alternation [164]. Consistently,
molecular differences in the activity of MEK1 and MEK2 have
been reported by several studies over the years. It was initially
shown that Ras and Raf1 form a signaling complex with MEK-
1, but not MEK-2 [165], and that upon EGF stimulation in HeLa
cells, Raf1 can activate both MEK1 and MEK2, whereas A-Raf
only activates MEK2 [166]. This may affect MEKs activity
during cell cycle progression, as reduction in MEK1, but not
MEK2, levels results in a G2/M arrest [162], and they also
demonstrate a differential effect on the G1/S phase of the cell
cycle [167].
Aside fromMEK1 andMEK2, an alternative spliced isoform
of MEK1, termed MEK1b, which lacks 26-amino acid residues
within its kinase domain, was identified in human [20,21].
Initial studies on this isoform indicated that it might be
catalytically inactive, and therefore, can be considered as a
dominant negative isoform of MEK1 [21]. However, recent
studies in our laboratory indicate that this isoform may be active
upon certain cellular stimulations (data not shown), and
therefore can function separately from MEK1 and MEK2
under restricted conditions. From the description above, it
seems that MEK1 and MEK2 might be functionally redundant
in the regulation of certain processes, but can exhibit unique
activities under other conditions to extend the specificity of the
ERK cascade.
In the MAPK tier, ERK1 and ERK2 are also very similar
proteins, with about 70% similarity between them, which is
higher in the kinase domain and lower in the flanking N- and
C-terminal regions [46]. Numerous studies using anti-ERK and
anti-phosphoERK antibodies revealed that the two isoforms are
expressed in essentially all cells and tissues in variable relative
amounts, whereby ERK2 is the predominant isoform in most
cells [168]. Usually, both proteins share similar activation
kinetics, cellular localization, and a set of substrates [168],
indicating that under most circumstances the two isoforms
function in a similar fashion. However, as described for MEKs,
some differences between the two isoforms do exist under
certain restricted conditions, and those differences are best
exemplified by the use of ERK1 and ERK2 knockout mice.
Thus, ERK1-deficient mice are viable, fertile, with normal size,
but manifest a deficit in thymocyte maturation [169]. More-
over, these mice exhibit an elevated synaptic plasticity in the
striatum, [170] which could be a result of a stimulus-dependent
elevation in ERK2 phosphorylation, which was observed in
neurons [170] as well as fibroblasts [169] of these mice.
Conversely, ERK2-deficient mice die early in development,
showing that ERK1 can't compensate for ERK2 in the embryo
[171–173].
More detailed studies with T-cell-specific knockout of ERK1
and ERK2 revealed that both kinases are essential for the
positive selection of T-cells. However, some of the downstream
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this tissue were dependent on the total ERKs activity, and
therefore, could be activated only by the more abundant ERK2
[174]. These results may therefore, indicate that some of the
differences in ERK1 and ERK2 functions are related to their
expression levels, and not so much to their actual substrates.
Nonetheless, recent results indicate that the changes in
expression are not always the cause of differences between
ERK1 and ERK2. Accordingly, it was shown that ERK1
participates in MEKs signaling during G2/M, while ERK2
seems to be essential during the G1 phase of the cell cycle [162].
Finally, unexpected differences between the two isoforms were
found during Ras-dependent signaling in fibroblasts [90,175],
where ablation of ERK1 promotes cell proliferation, while
ERK2 knockdown blocks this effect. These data suggest that
unlike the proliferation promoting effects of ERK2, ERK1 may
actually inhibit proliferation of Ras-transformed cells. Thus, in
similarity to MEKs, ERKs may have different effects under
certain conditions, and thereby, expend the specificity of the
cascade upon various stimulations.
Aside from the 44 kDa and 42 kDa ERK1 and ERK2, several
alternatively spliced isoforms seems to operate downstream of
MEKs in many cell lines and organisms. In rodents, a 46-kDa
ERK was identified, which is a product of a 26 amino acid
insertion into the CRS/CD of ERK1 [42]. Under many
circumstances, ERK1b behaves similarly to ERK1 and ERK2.
However, in Ras-transformed Rat1 cells, the expression levels
of ERK1b are elevated, the protein is activated in a different
kinetic than ERK1 and ERK2, and due to a phosphatase-
dependent lower activation of ERK1 and ERK2, ERK1b
becomes the major isoform that transmit extracellular signals
upon oncogenic transformation [42,176]. The unique function
of ERK1b is mainly caused by the interference with the function
of the CRS/CD domain, which changes its subcellular
localization, its regulatory phosphorylation/dephosphorylation
processes, and its interactions with its various substrates [176].
In primates, similar splicing events to those in rodents results
in the insertion of the same intron in close proximity to the
region encodes for CRS/CD. However, in this case the insert
contains a stop codon, and therefore, results in a 42-kDa protein,
termed ERK1c [43]. As for ERK1b, this protein has reduced
interactions with MKPs, MEKs and ERKs' substrates as
compared to ERK1 and ERK2, and therefore, is regulated
differently from the other ERKs. Interestingly, ERK1c was
demonstrated to possess unique functions that are not observed
in any of the other ERKs [43,177]. It was recently demonstrated
that ERK1c expression, phosphorylation and activity are
elevated during mitosis and in confluent cells as well. These
events are probably important for the transmission of MEKs
signals [178] that are required for the completion of mitotic and
elevated density Golgi fragmentation [177]. ERK1 and ERK2
do not participate in the regulation of these processes, indicating
that the alternatively spliced forms of ERKs exhibit unique
functions that extend the signaling specificity of the ERK
cascade. More functionally relevant, alternatively spliced forms
of ERKs are likely to be identified in the future, which will even
further extent the repertoire of ERKs targets.4. Summary
The ERK cascade is a central signaling component,
composed of protein kinases that sequentially phosphorylate
and activate each other. This cascade is stimulated by a large
variety of extracellular signals, and, as a consequence, regulates
many distinct and even opposing cellular processes, including
proliferation, differentiation, survival and even apoptosis. The
ability of the ERK cascade to initiate and regulate all these
effects raises the question as to how its specificity is determined.
In order to execute all its functions, the ERK cascade is heavily
regulated at several levels, mainly by different phosphatases,
but also by other interacting proteins. These regulatory
processes can be categorized into five distinct mechanisms
that are important for the specificity determination of the ERK
cascade. These include: (i) changes in the duration and strength
of the signals that are regulated mainly via inhibitory signaling
components, such as phosphatases that govern the induction of
various immediate early genes. (ii) Scaffold proteins that bring
components of the cascade to a close proximity to each other,
and direct them to the proper upstream and downstream effector
to facilitate their kinetic of activation. (iii) Subcellular
localization that is often influenced by certain anchoring
proteins, and direct the signals into their proper compartments
and targets. (iv) Crosstalk with other signaling pathway that
may influence the strength of the signals, and often modulates
the activity of downstream targets of the ERK cascade. (v) The
existence of multiple components with distinct functions in each
tier of the cascade, which can track the signal into different
specific targets for each of these components. As shown in this
review, many of these mechanisms can cooperate in order to
determine the final specificity of the cascade. Interestingly,
many of the mechanisms do not function properly in cancer
cells, and thereby, are probably involved in the induction and
maintenance of oncogenic transformation of many cell types.
Studying all these regulatory mechanisms can, therefore, lead to
a better understanding of oncogenic transformation and may
induce to a better design of drugs that can be used in the combat
of cancer.
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